.

Pharmaceutical Business Intelligence

  • Anticipate P&T budget requirements
  • Evaluate market entry opportunities
  • Find generic sources and suppliers
  • Predict branded drug patent expiration

► Plans and Pricing

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

DrugPatentWatch Database Preview

Claims for Patent: 8,603,506

« Back to Dashboard

Claims for Patent: 8,603,506

Title:Methods of treating acne
Abstract: A method of treating acne in a human in need thereof comprising administering systemically to said human a tetracycline compound in an amount that is effective to treat acne but has substantially no antibiotic activity, without administering a bisphosphonate compound.
Inventor(s): Ashley; Robert A. (Newtown, PA)
Assignee: Galderma Laboratories, Inc. (Fort Worth, TX)
Application Number:13/277,789
Patent Claims: 1. A method for treating papules and pustules of rosacea in a human in need thereof, the method comprising administering orally to said human doxycycline, or a pharmaceutically acceptable salt thereof, in an amount that (i) is effective to treat the papules and pustules of rosacea; (ii) is 10-80% of a 50 mg dose of doxycycline per day; and (iii) results in no reduction of skin microflora during a six-month treatment, without administering a bisphosphonate compound.

2. The method according to claim 1, wherein said doxycycline is doxycycline monohydrate.

3. The method according to claim 2, wherein said doxycycline monohydrate is administered in an amount of 40 milligrams.

4. The method according to claim 3, wherein said doxycycline monohydrate is administered by sustained release.

5. A method according to claim 4, wherein said doxycycline monohydrate is administered once a day.

6. The method according to claim 2, wherein said doxycycline monohydrate is administered in a dose of 20 mg twice a day.

7. The method according to claim 1, wherein said doxycycline, or a pharmaceutically acceptable salt thereof, is administered in an amount which provides a serum concentration in the range of about 0.1 to about 0.8 .mu.g/ml.

8. A method for treating papules and pustules of rosacea in a human in need thereof, the method comprising administering orally to said human doxycycline, or a pharmaceutically acceptable salt thereof, in an amount that (i) is effective to treat the papules and pustules of rosacea; (ii) is 40-80% of a 50 mg dose of doxycycline per day; and (iii) results in no reduction of skin microflora during a six-month treatment, without administering a bisphosphonate compound.

9. The method according to claim 8, wherein said doxycycline is doxycycline monohydrate.

10. The method according to claim 9, wherein said doxycycline monohydrate is administered in an amount of 40 milligrams.

11. The method according to claim 10, wherein said doxycycline monohydrate is administered by sustained release.

12. A method according to claim 11, wherein said doxycycline monohydrate is administered once a day.

13. The method according to claim 9, wherein said doxycycline monohydrate is administered in a dose of 20 mg twice a day.

14. The method according to claim 8, wherein said doxycycline, or a pharmaceutically acceptable salt thereof, is administered in an amount which provides a serum concentration in the range of about 0.1 to about 0.8 .mu.g/ml.

15. A method for treating papules and pustules of rosacea in a human in need thereof, the method comprising administering orally to said human doxycycline, or a pharmaceutically acceptable salt thereof, in an amount of 40 mg per day, wherein the amount results in no reduction of skin microflora during a six-month treatment, without administering a bisphosphonate compound.

16. The method according to claim 15, wherein said doxycycline is doxycycline monohydrate.

17. The method according to claim 16, wherein said doxycycline monohydrate is administered by sustained release.

18. A method according to claim 17, wherein said doxycycline monohydrate is administered once a day.

19. The method according to claim 16, wherein said doxycycline monohydrate is administered in a dose of 20 mg twice a day.

20. The method according to claim 15, wherein said doxycycline, or a pharmaceutically acceptable salt thereof, is administered in an amount which provides a serum concentration in the range of about 0.1 to about 0.8 .mu.g/ml.
« Back to Dashboard

For more information try a trial or see the database preview and plans and pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

`abc